Efficacy and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (GFF MDI) delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe COPD Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Critical handling errors with dry-powder, metered dose and soft-mist inhaler devices in an observational COPD study Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis) Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018
Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018
Breath activated inhaler usage and impact on rescue medication usage in patients with an asthma diagnosis: a prescribing claims study of 2823 patients using a CFC - pMDI and a breath-actuated device Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001
Real world handling performance of fluticasone propionate/salmeterol HFA MDI with an integrated dose counter in subjects with asthma or COPD Source: Eur Respir J 2005; 26: Suppl. 49, 127s Year: 2005
The asthmatic patient and inhaler treatment devices profile in Turkey: Asthma inhaler treatment study Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Budesonide/formoterol in a single inhaler sustains lung-function improvements in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003
Preference of the inhaler device and assessment of the technique among the asthmatic and COPD patients Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017
Training patients on how to use metered dose inhaler (MDI) by using the 2Tone will improve asthma quality of life (AQOL) Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Device handling study of a novel breath-actuated inhaler Synchrobreathe vs pMDI Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
Device handling study of a novel fluticasone propionate/formoterol breath-triggered inhaler Source: International Congress 2016 – Pulmonary drug delivery Year: 2016
Simulated-use study of inhaler usability in patients with COPD Source: International Congress 2017 – COPD management Year: 2017
Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
Efficacy in COPD patients of tiotropium administered via the Respimat® Soft MistÔ Inhaler (SMI) compared to HandiHaler® (HH) Source: Eur Respir J 2006; 28: Suppl. 50, 431s Year: 2006